Enhancing Immunogenicity of influenza vaccine in the elderly through intradermal vaccination: A literature analysis
HQ Quach, RB Kennedy - Viruses, 2022 - mdpi.com
Background: Aging and immunosenescence lead to a gradual decline in immune responses
in the elderly and the immunogenicity of influenza vaccines in this age group is sub-optimal …
in the elderly and the immunogenicity of influenza vaccines in this age group is sub-optimal …
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post‐vaccination but persist for at least 6 months
FL Mordant, OH Price, R Rudraraju… - Influenza and Other …, 2023 - Wiley Online Library
Abstract Background In Australia, seasonal inactivated influenza vaccine is typically offered
in April. However, the onset, peak and end of a typical influenza season vary, and optimal …
in April. However, the onset, peak and end of a typical influenza season vary, and optimal …
Relative effectiveness of MF59 adjuvanted trivalent influenza vaccine vs nonadjuvanted vaccines during the 2019–2020 influenza season
M Imran, J Puig-Barbera, JR Ortiz… - Open forum …, 2022 - academic.oup.com
Background Age-related immunosenescence may impair the immune response to
vaccination in older adults. Adjuvanted influenza vaccines are designed to overcome …
vaccination in older adults. Adjuvanted influenza vaccines are designed to overcome …
Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review
B Camilloni, M Basileo, S Valente… - Human vaccines & …, 2015 - Taylor & Francis
Because of the age-related immune system decline, 2 potentiated influenza vaccines were
specifically licensed for the elderly: Fluad®, an MF59-adjuvanted vaccine administered …
specifically licensed for the elderly: Fluad®, an MF59-adjuvanted vaccine administered …
Seasonal influenza immunisation: strategies for older adults
W Schaffner, P van Buynder, S McNeil… - … journal of clinical …, 2018 - Wiley Online Library
Adults over the age of 60‐65 years suffer disproportionally from seasonal influenza,
experiencing high rates of complications, exacerbation of underlying medical comorbidities …
experiencing high rates of complications, exacerbation of underlying medical comorbidities …
Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in …
EO Murchu, L Comber, K Jordan… - Reviews in Medical …, 2023 - Wiley Online Library
The most effective means of preventing seasonal influenza is through vaccination. In this
systematic review, we investigated the efficacy, effectiveness and safety of MF59® …
systematic review, we investigated the efficacy, effectiveness and safety of MF59® …
[HTML][HTML] A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza …
Y Levin, E Kochba, G Shukarev, S Rusch… - Vaccine, 2016 - Elsevier
Background Influenza remains a significant problem in elderly despite widespread
vaccination coverage. This randomized, phase-I study in elderly compared different …
vaccination coverage. This randomized, phase-I study in elderly compared different …
[HTML][HTML] Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults≥ 65 years of age: Meta-analysis of cumulative clinical …
U Nicolay, E Heijnen, P Nacci, PA Patriarca… - International Journal of …, 2019 - Elsevier
Objective Compare the immunogenicity of MF59-adjuvanted trivalent inactivated influenza
vaccine (aIIV3; Fluad™) versus conventional trivalent inactivated influenza vaccine (IIV3) in …
vaccine (aIIV3; Fluad™) versus conventional trivalent inactivated influenza vaccine (IIV3) in …
Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly
The influenza vaccination is known as the most effective method for preventing influenza
infection and its complications in the elderly. Conventional subunit (Agrippal S1; Novartis) …
infection and its complications in the elderly. Conventional subunit (Agrippal S1; Novartis) …
Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older
RB Couch, JM Bayas, C Caso, IN Mbawuike… - BMC infectious …, 2014 - Springer
Background The effectiveness of trivalent influenza vaccines may be reduced in older
versus younger adults because of age-related immunosenescence. The use of an adjuvant …
versus younger adults because of age-related immunosenescence. The use of an adjuvant …